Single Cell Technology (SCT) and AB Biosciences have entered a collaboration to identify therapeutic antibodies.
SCT will utilize its patented platform to massively screen plasma cells, measure the kinetics of secreted antibodies, and sequence the cognate light and heavy chain mRNA powered by next generation sequencing. AB will select antibody targets, engineer protein antigens, and develop analytical tools to further characterize the large panel of antibodies identified by SCT’s platform.
“SCT has developed an innovative antibody discovery platform. Together with AB Biosciences’ premier protein engineering capacity and astute insights in antibody drug development, we will utilize our platform to outperform traditional antibody discovery techniques,” said Chun-Nan Chen, M.D., founder and CEO of SCT.